Ramipril

雷米普利

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameRamipril
Drug Alias Name雷未普利QuarkHypren雷米普剂Vesdil +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin-converting enzyme inhibitors
TargetsAngiotensin-converting enzyme
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cognition DisordersFibrosis +[22] 
Global Approved IndicationsHypertensionMyocardial InfarctionHeart Failure +[5] 
Approved Indications in ChinaHypertensionMyocardial InfarctionHeart Failure +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date1991/01/28
Country/TerritoryCanadaUnited StatesUkraine +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesHetero Drugs LtdIndonesia University
Inactive CompaniesSandozFederal University Of Sao PauloUniversity of Zurich +[15] 
Active IndicationsCognition DisordersFibrosisHypertension +[10] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Metabolic SyndromeDiabetes Mellitus, Type 1 +[12] 

Other Information

ATC CodeC09AA05
Related LinksWikipediaDrugBankKEGG